Keybank National Association OH cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 27.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,822 shares of the medical research company’s stock after selling 2,181 shares during the period. Keybank National Association OH’s holdings in Charles River Laboratories International were worth $1,718,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Handelsbanken Fonder AB boosted its stake in Charles River Laboratories International by 36.9% during the second quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock worth $4,378,000 after buying an additional 5,200 shares in the last quarter. Avidity Partners Management LP bought a new stake in Charles River Laboratories International in the 1st quarter valued at $1,670,000. Evergreen Capital Management LLC bought a new stake in Charles River Laboratories International in the 3rd quarter valued at $2,621,000. Quantitative Investment Management LLC acquired a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $1,360,000. Finally, Madison Asset Management LLC acquired a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $3,805,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on CRL. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Robert W. Baird upped their target price on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. UBS Group increased their price target on shares of Charles River Laboratories International from $357.00 to $387.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Charles River Laboratories International in a research report on Monday, September 28th. Finally, Jefferies Financial Group raised their price target on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $311.67.
Charles River Laboratories International Price Performance
NYSE:CRL traded down $2.54 during trading hours on Friday, reaching $338.27. The company had a trading volume of 838,240 shares, compared to its average volume of 1,294,316. The stock has a 50-day moving average of $311.21 and a two-hundred day moving average of $228.24. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $379.63. The firm has a market capitalization of $16.21 billion, a PE ratio of 371.73, a PEG ratio of 3.08 and a beta of 1.36. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million during the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The business’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.43 earnings per share. Analysts forecast that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.
Insider Transactions at Charles River Laboratories International
In related news, EVP Shannon M. Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total transaction of $742,547.96. Following the completion of the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,655,578.87. This trade represents a 30.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the transaction, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. This represents a 28.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 63,352 shares of company stock valued at $20,291,281. 1.30% of the stock is owned by insiders.
Charles River Laboratories International Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Further Reading
- Five stocks we like better than Charles River Laboratories International
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
